Neuroprotective properties of valproate: Potential benefit for AD and Tauopathies

Journal of Molecular Neuroscience

Volumn 19, Issue 3, 2002, Pages 303-307

  Loy, Rebekah ^a,b   Tariot, Pierre N ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Alzheimer's disease; Anticonvulsants; Kinase; Neurodegeneration; Neurofibrillary tangles; Phosphorylation

Indexed keywords

ANTICONVULSIVE AGENT; BETA CATENIN; CARBAMAZEPINE; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN BCL 2; TAU PROTEIN; VALPROIC ACID;

AGITATION; ALZHEIMER DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; ENZYME INHIBITION; HUMAN; MENTAL DISEASE; NEUROPROTECTION; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 0036931742     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/jmn:19:3:301     Document Type: Review

References (24)

1. Chen G., Huang L. D., Jiang Y. M., and Manji H. K. (1999) The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72, 1327-1330.
2. Cohen P. and Frame S. (2001) The renaissance of GSK3. Nat. Rev.: Mol. Cell Biol. 2, 769-776.
3. Cohen-Mansfield J. and Werner P. (1998) Longitudinal changes in behavioral problems in old age: A study in an adult day care population. J. Gerontol. A. Biol. Sci. Med. Sci. 53, M65-M71.
4. Cummings J. L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D. A., and Gornbein J. (1994) The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
5. Farber N. B., Rubin E. H., Newcomer J. W., Kinscherf D. A., Miller J. P., Morris J. C., et al. (2000) Increased neocortical neurofibrillary tangle density in subjects with alzheimer disease and psychosis. Arch. Gen. Psychiatry 57, 1165-1173.
6. Finkel S. I., Costa, Cohen G., Miller S., and Sartorius N. (1996) Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Int. Psychogeriatr. 8(Suppl. 3), 497-500.
7. Grimes C. A. and Jope R. S. (1999) Cholinergic stimulation of early growth response-1 DNA binding activity requires protein kinase C and mitogen-activated protein kinase kinase activation and is inhibited by sodium valproate in SH-SY5Y cells. J. Neurochem. 73, 1384-1392.
8. Hoshi M., Takashima A., Noguchi K., Murayama M., Sato M., Kondo S., et al. (1996) Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc. Natl. Acad. Sci. USA 93, 2719-2723.
9. Imahori K. and Uchida T. (1997) Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. 121, 179-188.
10. Imahori K., Hoshi M., Ishiguro K., Sato K., Takahashi M., Shiurba R., et al. (1998) Possible role of tau protein kinases in pathogenesis of Alzheimer's disease. Neurobiol. Aging 19. S93-S98.
11. Leibovici A. and Tariot P. N. (1988) Carbamazepine treatment of agitation associated with dementia. J. Geriatr. Psychiatry Neurol. 1, 110-112.
12. Lyketsos C. G., Steinberg M., Tschanz J. T., Norton M. C., Steffens D. C., and Breitner J. C. (2000) Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry 157, 708-714.
13. Mark R. J., Ashford J. W., Goodman Y., and Mattson M. P. (1995) Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol. Aging 16, 187-198.
14. Paulsen J. S., Salmon D. P., Thal L. J., Romero R., Weisstein-Jenkins C., Galasko D., et al. (2000) Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 54, 1965-1971.
15. Porsteinsson A. P., Tariot P. N., Erb R., et al. (2001) Placebo-controlled study of divalproex sodium for agitation in dementia. Am. J. Geriat. Psychiatry 9, 58-66.
16. Sun X., Sato S., Murayama O., et al. (2002) Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. 321, 61-64.
17. Tariot P. and Blazina L. (1993) The psychopathology of dementia, in Handbook of Dementing Illnesses (Morris J., ed.), Marcel Dekker, New York, pp. 461-475.
18. Tariot P. N., Schneider L. S., and Katz I. R. (1995) Anti-convulsant and other non-neuroleptic treatment of agitation in dementia. J. Geriatr. Psychiatry Neurol. 8(Suppl. 1), S28-S39.
19. Tariot P. N., Erb R., Podgorski C. A., Cox C., Patel S., Jakimovich L., et al. (1998) Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am. J. Psychiatry 155, 54-61.
20. Tariot P. N., Schneider L., Mintzer J., Cutler A., Cunningham M., Thomas J., et al. (2001) Safety and tolerability of divalproex sodium for the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial. Curr. Therapeut. Res. 62, 51-67.
21. Tekin S., Mega M. S., Masterman D. M., Chow T., Garakian J., Vinters H. V., et al. (2001) Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann. Neurol. 49, 355-361.
22. Thal D. R., Holzer M., Rub U., Waldmann G., Gunzel S., Zedlick D., et al. (2000) Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp. Neurol. 163, 98-110.
23. Tong N., Sanchez J. F., Maggirwar S. B., et al. (2001) Activation of glycogen synthase kinase 3 beta (GSK-3β) by platelet activating factor mediates migration and cell death in cerebral granule neurons. Eur. J. Neurosci. 13, 1913-1922.
24. van Gijn M. E., Snel F., Cleutjens J. P., et al. (2001) Over-expression of components of the Frizzled-Dishevelled cascade results in apoptotic cell death, mediated by β-catenin, Exp. Cell. Res. 265, 46-53.